Effect of DPP-4 inhibitor or Metformin on insulin therapy in patients with type 2 diabetes

Not Applicable

• Conditions: Type 2 diabetes

• Registration Number: JPRN-UMIN000008155
• Lead Sponsor: Divison of Diabetes and Metabolism,Itabashi Hospital, Nihon University School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-06-13
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with glucagnoma 2) Patients who started in the cure for the past three months 3) Patients who changed in the cure for the past three months 4) Patients with type 1 diabetes.Patients with type 2 diabetes HbA1c>=10.5% or severe ketosis,diabetic coma. 5) Patients treated with oral hypoglycemic agents 6) Patients with nephrosic syndrome 7) Patients treated with steroid, immune-suppressive agent and azole antifungal 8) Patients with allergy against sitagliptin and metformin 9)Patients with exceeding the moderate renal impairment (sCr: male>=1.3mg/dl, female>=1.2mg/dl). 10)Patients with exceeding the moderate liver dysfunction (AST,ALT>3 times upper standard value). 11)Patients who are pregnant, breast-feeding and/or intention to become pregnant 12)Other patients determined to be inappropriate by physician

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change of glucose, glucagon and C-peptide response to MTT after sitagliptin or metformin treatment.

Secondary Outcome Measures

Name	Time	Method
Change of HbA1c, fasting plasma glucose, glucagon and C-peptide after sitagliptin or metforimin treatment.